Experimental drug aims to treat dangerous blood reaction to common blood thinner
Disease control
Terminated
This study tested an experimental drug called VLX-1005 in people with a rare condition called heparin-induced thrombocytopenia (HIT), where a common blood thinner causes low platelets and dangerous blood clots. About 24 adults with suspected HIT received either VLX-1005 or a plac…
Phase: PHASE2 • Sponsor: Veralox Therapeutics • Aim: Disease control
Last updated May 26, 2026 17:15 UTC